Amgen reported steady revenue growth and strong performance from new products like Prolia and XGEVA, which highlight promising future avenues. Although operating expenses increased and some legacy product sales declined, the reaffirmation of guidance and strategic investments in R&D suggest confidence in sustained growth. Investors are likely to view the positive momentum from new products favorably in the short term.

[1]